

## POLICY &amp; PRACTICE

**Fla. Ruling Affects Levothyroxine Rx**

A ruling by a Florida administrative law judge means pharmacists in that state now are free to substitute generic levothyroxine sodium for brand-name formulations of the drug. The January decision that removed Synthroid, Levoxyl, Levotheroid, and Unithroid from the negative formulary list came in response to a petition last August by Mylan Inc., which markets a generic form of levothyroxine. Prescriptions for drugs on a negative formulary list may not be substituted. Judge Susan B. Harrell noted in her decision that Abbott

argued that removing levothyroxine from the negative drug formulary would endanger patients because pharmacists could substitute a generic drug which is not therapeutically equivalent to the prescribed brand-name drug. However, that issue is already covered by existing laws on generic substitution, she added. "The legislature has left it to the professional judgment of licensed pharmacists to determine what substitutions would not pose a threat to the health and safety of the patients," Judge Harrell wrote. In an alert to its Florida members, the American Asso-

ciation of Clinical Endocrinologists noted that as a result of the ruling, "the only way to ensure your prescription or refill order is honored to your specifications is to write 'Medically Necessary' on the prescription." Abbott Laboratories, which makes Synthroid, has filed an appeal.

**Baseball Drug Exemptions Skyrocket**

The number of "therapeutic use exemptions" given to Major League Baseball players tripled between 2006 and 2007, according to statistics recently released by the House Oversight and Government Reform Committee. In 2007, MLB granted 111 exemptions, compared with 35 in

2006. Of the 111 exemptions granted last year, 103 were for medications to treat attention-deficit/hyperactivity disorder; 5 were for treating hypertension, 1 was for treating alopecia areata, and 2 were for treating androgen deficiency. Of the 35 granted in 2006, 28 were for ADHD, 4 were for hypertension, and 3 were for androgen deficiency. The ADHD exemptions in 2007 "would appear to be an exceptionally high percentage, somewhat over ... eight times the percentage of regular adults taking [ADHD] medication in our population," John Tierney (D-Mass.), committee member, said at a hearing on steroid use in Major League Baseball. MLB Commissioner Bud Selig said the exemptions were "within the limit of the adult population. ... We are reviewing that right now, trying to break down exactly why it happened and how it happened."

**Pay for Remote Monitoring**

Reimbursement for remote monitoring may be added to a Medicare physician fee fix bill when it is taken up later this year, officials from AdvaMed, a lobbying group for medical device companies, said at a briefing last month. AdvaMed has met with staff from the Centers for Medicare and Medicaid Services to discuss coding for remote management of conditions such as heart failure, cardiac arrhythmia, diabetes, sleep apnea, and epilepsy. The coding discussions may provide the necessary momentum, said Stephen J. Ubl, AdvaMed president and CEO. The device lobby estimates that remote monitoring would cost \$100 million or less over a 5-year period. Mr. Ubl also expressed hope that the Medicare package will include funds for a demonstration project to test a new payment system for certain molecular diagnostics. That would fix a flawed system, which pays less for new tests that may offer greater value to patients, he said. The pilot proposal is in S. 2404, which is sponsored by Sen. Chuck Schumer (D-N.Y.).

**ACC on Vytarin Queries**

The American College of Cardiology said it is cooperating with the House Energy and Commerce Committee on its requests to furnish information on funds the college has received from Merck & Co./Schering-Plough Corp., the joint venture that makes and sells Vytarin (ezetimibe/simvastatin). The drug combination has been the subject of intense scrutiny by the committee, largely because of delays in releasing data from the ENHANCE study. The committee said it wanted to know the nature of financial contributions made by the drug companies because the ACC and the American Heart Association had issued statements urging patients not to stop taking Vytarin without talking to their physicians first. The committee also requested data from the American Heart Association. Rep. Bart Stupak (D-Mich.), chairman of the oversight and investigations subcommittee, said his panel would look at "how they use this funding and any potential conflicts of interest." An ACC spokesperson said the organization had delivered boxes of material to the committee, adding, "industry support in no way affects our policies."

—Joyce Frieden

**REGISTER NOW!**

## Family Practice News® &amp; Internal Medicine News®

and

**Boston University School of Medicine****JOINTLY SPONSOR****Endocrinology in the News**

**A Continuing Medical Education Conference designed for all health care professionals involved in the management of metabolic disorders and other issues related to endocrinology.**

**April 12 – 13, 2008****Loews Philadelphia Hotel, Philadelphia****Topic Highlights**

Preventing Type 2 Diabetes and Cardiovascular Disease: Lessons From Recent Trials

Incretins – What's Here and What's Coming?

Metabolic Syndrome – Why the Controversy?

Should We Care About HDL Cholesterol?

Nutritional Approach to Obesity: High vs. Low Carb Diet?

Conditions and Comorbidities Affecting Thyroid Function Tests

When to Suspect Adrenal Hypertension

Testosterone Replacement and the Aging Baby Boomer

The Differential Diagnosis of Thin Bones

Bisphosphonates and Recombinant PTH: Indications, Benefits and Complications

Vitamin D Therapy – Expanding Clinical Applications

PCOS and Fertility

Estrogen Therapy and the Menopausal Woman

Case Presentations... and more

**Tuition****Physicians:****Early Bird: \$450**After Feb. 15<sup>th</sup>: \$495**Nurses:****Early Bird: \$300**After Feb. 15<sup>th</sup>: \$325**Accommodations****Loews Philadelphia Hotel** (215) 627-1200

Mention the *Family Practice News*, *Internal Medicine News* and *Boston University School of Medicine* group to receive the special rate of **\$199 per night**.

**Educational Needs Addressed:** This conference will provide participants with a comprehensive review of endocrinologic and metabolic disorders, presenting up-to-date information in the diagnosis and management of these disorders, including diabetes mellitus, osteoporosis, obesity, pituitary illnesses and androgen-related problems such as polycystic ovary syndrome (PCOS).

**Educational Objectives:** At the conclusion of this conference, participants will be able to:

- Implement new treatment strategies in compliance with guidelines and the latest advances in the management of metabolic disorders.
- Prepare a checklist of signs and symptoms to identify metabolic disorders in patients within your practice.
- Predict causes of obesity and co-morbidities when assessing your patient's health.
- Apply the latest guidelines for diabetes control and complications of thyroid disorders, hypertension, and osteoporosis.

**Accreditation:** This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Elsevier/IMNG. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of **10.5 AMA PRA Category 1 Credit(s)**™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Application for CME credit has been filed with the American Academy of Family Physicians. **Determination of credit is pending.**

**Check our websites for conference updates:**

[www.bu.edu/cme](http://www.bu.edu/cme)

[www.familypracticenews.com](http://www.familypracticenews.com)

[www.internalmedicinews.com](http://www.internalmedicinews.com)

This program is being supported in part by an educational grant from

**Course Director**

**Elliot Sternthal, MD**  
Clinical Director of Diabetes Services  
Boston Medical Center  
Assistant Professor of Medicine  
Boston University School of Medicine

**Faculty**

**Shalender Bhasin, MD**  
Boston Medical Center  
Boston University School of Medicine

**Susan S. Braithwaite, MD**  
University of North Carolina School of Medicine

**Seth Braunstein, MD, PhD**  
Hospital of the University of Pennsylvania  
University of Pennsylvania

**Andrea Coviello, MD, MSE**  
Boston University School of Medicine

**Diana Cullum-Dugan, RD, LD**  
Boston Medical Center

**Alan Farwell, MD**  
Boston Medical Center  
Boston University School of Medicine

**Osama Hamdy, MD, PhD**  
Joslin Diabetes Center  
Harvard Medical School

**Stephanie Lee, MD, PhD**  
Boston Medical Center  
Boston University School of Medicine

**Alan Malabanan, MD**  
Beth Israel Deaconess Medical Center  
Harvard Medical School

**Norman A. Mazer, MD, PhD**  
Boston Medical Center  
Boston University School of Medicine

**Marie E. McDonnell, MD**  
Boston Medical Center

**George J. Philippides, MD, FACC**  
Boston Medical Center  
Boston University School of Medicine

**Ernst J. Schaefer, MD**  
Tufts University School of Medicine  
Friedman School of Nutrition, Science and Policy

**Vin Tangpricha, MD, PhD**  
The Emory Clinic  
Emory University School of Medicine

**Andrea L. Utz, MD, PhD**  
Massachusetts General Hospital  
Harvard University

**To register, please contact:**

**Boston University  
School of Medicine**

**Continuing Medical Education**

715 Albany Street, A305  
Boston, MA, 02118

Phone: (617) 638-4605

Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: [cme@bu.edu](mailto:cme@bu.edu)

Website: <http://www.bu.edu/cme>